This analysis explores improved outcomes from mechanical thrombectomy in acute ischemic stroke, suggesting broader applications for treatment.
Mechanical thrombectomy has transformed the management of acute ischemic stroke caused by large vessel occlusion, evolving from early intra-arterial thrombolysis and first-generation devices into a Class I, Level A standard of care in anterior circulation stroke. Landmark randomized trials and pooled analyses have demonstrated robust improvements in functional independence with early-window, late-window, posterior circulation, and now large-core thrombectomy. Recent large-core trials show that carefully selected patients with substantial baseline infarction can still derive meaningful benefit from endovascular therapy, challenging traditional exclusion thresholds. In contrast, randomized medium- and distal-vessel occlusion (MeVO/DVO) studies to date have been neutral, emphasizing the need for more refined patient selection and dedicated small-vessel devices. Ongoing platform trials, advances in devices and combined techniques, and AI-enabled workflow optimization are poised to further expand the horizons of mechanical thrombectomy, particularly in resource-limited settings and previously undertreated stroke populations.
No takes yet. Share an insight, caveat, or question.
Akash et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: